Muscle weakness in cancer survivors may be caused by treatable weakness in blood vessels: new research
By Jalees Rehman
Tumors can destroy the blood vessels of muscles even when the muscles are nowhere close to the tumor. That is the key finding of a new study that my colleagues and I recently published in the journal Nature Cancer.
Muscle loss in cancer patients is a major health problem, but the exact causes of how precisely tumors affect muscles remain an active area of research.
Scientists in my lab were curious whether one explanation for the muscle loss in cancer patients could be that the cancer impairs the blood vessels that are necessary to supply nutrients and oxygen to muscles. Healthy blood vessels ensure that blood containing oxygen and nutrients is transported from the heart to all tissues and organs in the body, and then circulates back to the heart. Unhealthy blood vessels lose the ability to circulate sufficient blood and develop leaks, with nutrients seeping into the tissue prematurely and thereby cutting off the supply of nutrients to tissues that are further downstream.
To tackle this question, my colleagues and I worked with several other scientific research teams with expertise in advanced microscopy, cancer research and metabolism. We used animal models to study several kinds of tumors – lung cancer, skin cancer, colon cancer and pancreatic cancer. We consistently observed that the blood vessels in the muscles became fewer and leakier even before the muscle weakness set in.
We also found that tumors release a protein called Activin-A, which acts on blood vessels to cause the leakiness and, ultimately, loss of blood vessels in the muscle. When we used a gene therapy to restore blood vessel health by counteracting the effects of Activin-A, we were able to prevent the muscle loss.
So we examined the muscles of patients who had passed away because of cancer and found that the muscles of cancer patients contained fewer blood vessels than expected.
Why Activin-A matters
Millions of cancer survivors struggle with muscle weakness, which can be so profound that they may have difficulties walking up a couple of flights of stairs or going shopping for groceries on their own.
Severe muscle weakness and muscle loss during cancer is called cancer cachexia, which occurs in up to 80% of patients with advanced cancer.
Recent research indicates that cachexia is far more common among cancer patients than previously suspected, with approximately half the patients who see their cancer doctor for the first time already showing signs of muscle weakness.
Importantly, cachexia can persist even after the cancer is successfully treated and cured. This can have a devastating impact on the quality of life for cancer survivors.
Our discovery that the loss of blood vessel function in the muscles occurs early on during the progression of the cancer suggests that fixing blood vessels in cancer patients and cancer survivors could be a new way to prevent or reverse cachexia.
The reasons for the muscle loss in cancer are complicated and involve poor nutrition due to loss of appetite and inflammation, which are initially caused by the tumor but persist even when the tumor is removed.
What other research is being done
There are currently no treatments approved by the Food and Drug Administration for cachexia, but new therapies are on the horizon.
One such therapy is an antibody drug that targets the molecule GDF-15, a protein that is thought to suppress appetite.
Other studies are using a combination of targeted nutrition and exercise programs to help patients with cancer cachexia regain muscle mass and muscle strength.
All these studies suggest that we will need a combination of approaches to enhance exercise, nutrition, appetite, muscle regeneration and – as we propose – blood vessel health.
What's next
We are now evaluating drugs and exercise programs that are known to improve blood vessel health. Repurposing these treatments that are traditionally designed for cardiovascular patients could be a rapid way to help cancer patients regain muscle strength.
We hope that our work highlights how important it is for cancer patients to receive comprehensive medical care, which includes improving cardiovascular health and overall quality of life.
Jalees Rehman is Department Chair and Professor of Biochemistry and Molecular Genetics, University of Illinois Chicago.
The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.
External Link
https://theconversation.com/muscle-weakness-in-cancer-survivors-may-be-caused-by-treatable-weakness-in-blood-vessels-new-research-259765
© The Conversation
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Today
12-08-2025
- Japan Today
Vaccines hold tantalizing promise in the fight against dementia
By Anand Kumar and Jalees Rehman Over the past two centuries, vaccines have been critical for preventing infectious diseases. The World Health Organization estimates that vaccination prevents between 3 million and 5 million deaths annually from diseases like diphtheria, tetanus, influenza, measles and, more recently, COVID-19. While there has long been broad scientific consensus that vaccines prevent or mitigate the spread of infections, there is new research suggesting that the therapeutic impact might go beyond the benefit of preventing infectious diseases. An April study published in the prominent journal Nature found tantalizing evidence that the herpes zoster – or shingles – vaccine could lower the risk of dementia in the general population by as much as 20%. We are a team of physician scientists with expertise in the clinical and basic science of neurodegenerative disorders and dementia. We believe that this study potentially opens the door to other breakthroughs in understanding and treating dementia and other degenerative disorders of the brain. A role for vaccines in reducing dementia risk? One of the major challenges researchers face when trying to study the effects of vaccines is finding an unvaccinated 'control group' for comparison – a group that is similar to the vaccine group in all respects, save for the fact that they haven't received the active vaccine. That's because it's unethical to assign some patients to the control group and deprive them of vaccine protection against a disease such as shingles. The Nature study took advantage of a policy change in Wales that went into effect in 2013, stating that people born on or after September 2, 1933, were eligible for the herpes zoster vaccination for at least a year, while those born before that cutoff date were not. The vaccine was administered to prevent shingles, a painful condition caused by the same virus that causes chickenpox, which can lie dormant in the body and be reactivated later in life. The researchers used the policy change as a natural laboratory of sorts to study the effect of shingles vaccination on long-term health outcomes. In a statistically sophisticated analysis of health records, the team found that the vaccine reduced the probability of getting dementia by one-fifth over a seven-year period. This means that people who received the shingles vaccine were less likely to develop clinical dementia over the seven-year follow-up period, and women benefited more than men. The study design allowed researchers to compare two groups without actively depriving any one group of access to vaccination. The two groups were also of comparable age and had similar medical comorbidities – meaning similar rates of other medical conditions such as diabetes or high blood pressure. Results from this and other related studies raise the possibility that vaccines may have a broader role in experimental therapeutics outside the realm of infectious diseases. These studies also raise provocative questions about how vaccines work and how our immune system can potentially prevent dementia. How vaccines might be protective One scientific explanation for the reduction of dementia by the herpes zoster vaccine could be the direct protection against the shingles virus, which may play a role in exacerbating dementia. However, there is also the possibility that the vaccine may have conferred protection by activating the immune system and providing 'trained immunity,' in which the immune system is strengthened by repeated exposure to vaccines or viruses. The study did not differentiate between different types of dementia, such as dementia due to Alzheimer's disease or dementia due to stroke. Additionally, researchers cannot draw any definitive conclusions about possible mechanisms for how the vaccines could be protective from an analysis of health records alone. The next step would be a prospective, randomized, double-blind, placebo-controlled study – the 'gold standard' for clinical trials in medicine – to directly examine how the herpes zoster vaccine compares with a placebo in their ability to reduce the risk of dementia over time. Such studies are necessary before any vaccines, as well as other potential therapies, can be recommended for routine clinical use in the prevention of dementia. The challenges of untangling dementia Dementia is a major noncommunicable disease that is a leading cause of death around the world. A January 2025 study provided updated figures on lifetime dementia risk across different subsets of the U.S. population. The researchers estimate that the lifetime risk of dementia after age 55 is 42% – more than double earlier estimates. The dementia risk was 4% by age 75, and 20% by age 85, with the majority of risk occurring after 85. The researchers projected that the number of new cases of dementia in the U.S. would double over the next four decades from approximately 514,000 cases in 2020 to 1 million in 2060. Once considered a disease largely confined to the developed world, the deleterious effects of dementia are now apparent throughout the globe, as life expectancy increases in many formerly developing countries. While there are different forms of dementia with varying clinical manifestations and underlying neurobiology, Alzheimer's disease is the most common. Prospective studies that specifically test how giving a vaccine changes the risk for future dementia may benefit from studying patient populations with specific types of dementia because each version of dementia might require distinct treatments. Unfortunately, for the past two to three decades, the amyloid hypothesis of Alzheimer's disease – which posits that accumulation of a protein called amyloid in the brain contributes to the disorder – dominated the scientific conversation. As a result, most of the efforts in the experimental therapeutics of Alzheimer's disease have focused on drugs that lower the levels of amyloid in the brain. However, results to date have been modest and disappointing. The two recently approved amyloid-lowering therapies have only a minimal impact on slowing the decline, are expensive and have potentially serious side effects. And no drug currently approved by the Food and Drug Administration for clinical use reverses the cognitive decline. Studies based on health records suggest that past exposure to viruses increase the risk of dementia, while routine vaccines, including those against tetanus, diphtheria, pertussis, pneumonia, shingles and others, reduce the risk. Innovation and an open mind There is sometimes a tendency among scientists to cling to older, familiar models of disease and a reluctance to move in more unconventional directions. Yet the process of doing science has a way of teaching researchers like us humility, opening our minds to new information, learning from our mistakes and going where that data takes us in our quest for effective, lifesaving therapies. Vaccines may be one of those paths less traveled. It is an exciting possibility that may open the door to other breakthroughs in understanding and treating degenerative disorders of the brain. Anand Kumar is Professor and Department Head of Psychiatry, University of Illinois Chicago. Jalees Rehman is Department Chair and Professor of Biochemistry and Molecular Genetics, University of Illinois Chicago. The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts. External Link © The Conversation
Asahi Shimbun
02-08-2025
- Asahi Shimbun
Astronauts launch to the space station after sidelined by Boeing's troubled Starliner
Astronaut Kimiya Yui, of Japan gestures as he leaves the Operations and Checkout Building for a trip the Kennedy Space Center's Launch Pad 39-A and a planned liftoff on a SpaceX Falcon 9 rocket on Aug. 1 in Cape Canaveral, Fla. (AP Photo) CAPE CANAVERAL, Fla.--Astronauts sidelined for the past year by Boeing's Starliner trouble blasted off to the International Space Station on Friday, getting a lift from SpaceX. The U.S.-Japanese-Russian crew of four rocketed from NASA's Kennedy Space Center. They'll replace colleagues who launched to the space station in March as fill-ins for NASA's two stuck astronauts. Their SpaceX capsule should reach the orbiting lab this weekend and stay for at least six months. Zena Cardman, a biologist and polar explorer who should have launched last year, was yanked along with another NASA crewmate to make room for Starliner's star-crossed test pilots. 'I have no emotion but joy right now. That was absolutely transcendent. Ride of a lifetime,' Cardman, the flight commander, said after reaching orbit. The botched Starliner demo forced Butch Wilmore and Suni Williams to switch to SpaceX to get back from the space station more than nine months after departing on what should have been a weeklong trip. 'Every astronaut wants to be in space. None of us want to stay on the ground, but it's not about me,' Cardman said before her flight. NASA's Mike Fincke — Cardman's co-pilot — was the backup for Wilmore and Williams on Starliner, making those three still the only ones certified to fly it. Fincke and Japan's Kimiya Yui, former military officers with previous spaceflight experience, were training for Starliner's second astronaut mission. With Starliner grounded until 2026, NASA switched the two to the latest SpaceX flight. 'Boy, it's great to be back in orbit again,' Fincke radioed. He last soared on NASA's next-to-last space shuttle flight in 2011. Rounding out the crew is Russia's Oleg Platonov. The former fighter pilot was pulled a few years ago from the Russian Soyuz flight lineup because of an undisclosed health issue that he said has since been resolved. On hand for the first launch attempt on Thursday, NASA's new acting administrator, Transportation Secretary Sean Duffy, met with Roscosmos director general Dmitry Bakanov, an invited guest. The two discussed future collaboration, then left town after thick clouds forced a last-minute delay. 'What we learn on these missions is what's going to get us to the moon and then from the moon to Mars, which is I think the direction that NASA has to be,' Duffy said in a NASA interview. 'There's critical real estate on the moon. We want to claim that real estate for ourselves and our partners.' To save money in light of tight budgets, NASA is looking to increase its space station stays from six months to eight months, a move already adopted by Russia's space agency. SpaceX is close to certifying its Dragon capsules for longer flights, which means the newly launched crew could be up there until April. NASA is also considering smaller crews — three astronauts launching on SpaceX instead of the typical four — to cut costs. As for Starliner, NASA is leaning toward launching the next one with cargo before flying another crew. Engineers are still investigating the thruster failures and helium leaks that bedeviled Starliner following liftoff. Time is running out as NASA looks to abandon the aging space station by 2030. An air leak on the Russian side of the station remains unresolved after years of patching. Engineering teams already are working on the plan for the space station's last days. NASA's Ken Bowersox said the U.S. and Russia need to cooperate in order to steer the outpost into the Pacific with minimal risk to the public. It will take at least two years to get the space station low enough to where a SpaceX vehicle can provide the final shove. Thrusters on the Russian side of the station will help with control, but that means more fuel will have to be delivered by 2028. The latest timeline calls for SpaceX to launch the last mission for NASA — the deorbit vehicle — to the space station in 2029. Astronauts would remain on board until the last four to six months of the station's life to handle any breakdowns, with the empty outpost plunging into the Pacific by late 2030 or early 2031.
Japan Today
30-07-2025
- Japan Today
Muscle weakness in cancer survivors may be caused by treatable weakness in blood vessels: new research
Poorly functioning blood vessels lead to the characteristic muscle weakness that so many cancer patients experience. By Jalees Rehman Tumors can destroy the blood vessels of muscles even when the muscles are nowhere close to the tumor. That is the key finding of a new study that my colleagues and I recently published in the journal Nature Cancer. Muscle loss in cancer patients is a major health problem, but the exact causes of how precisely tumors affect muscles remain an active area of research. Scientists in my lab were curious whether one explanation for the muscle loss in cancer patients could be that the cancer impairs the blood vessels that are necessary to supply nutrients and oxygen to muscles. Healthy blood vessels ensure that blood containing oxygen and nutrients is transported from the heart to all tissues and organs in the body, and then circulates back to the heart. Unhealthy blood vessels lose the ability to circulate sufficient blood and develop leaks, with nutrients seeping into the tissue prematurely and thereby cutting off the supply of nutrients to tissues that are further downstream. To tackle this question, my colleagues and I worked with several other scientific research teams with expertise in advanced microscopy, cancer research and metabolism. We used animal models to study several kinds of tumors – lung cancer, skin cancer, colon cancer and pancreatic cancer. We consistently observed that the blood vessels in the muscles became fewer and leakier even before the muscle weakness set in. We also found that tumors release a protein called Activin-A, which acts on blood vessels to cause the leakiness and, ultimately, loss of blood vessels in the muscle. When we used a gene therapy to restore blood vessel health by counteracting the effects of Activin-A, we were able to prevent the muscle loss. So we examined the muscles of patients who had passed away because of cancer and found that the muscles of cancer patients contained fewer blood vessels than expected. Why Activin-A matters Millions of cancer survivors struggle with muscle weakness, which can be so profound that they may have difficulties walking up a couple of flights of stairs or going shopping for groceries on their own. Severe muscle weakness and muscle loss during cancer is called cancer cachexia, which occurs in up to 80% of patients with advanced cancer. Recent research indicates that cachexia is far more common among cancer patients than previously suspected, with approximately half the patients who see their cancer doctor for the first time already showing signs of muscle weakness. Importantly, cachexia can persist even after the cancer is successfully treated and cured. This can have a devastating impact on the quality of life for cancer survivors. Our discovery that the loss of blood vessel function in the muscles occurs early on during the progression of the cancer suggests that fixing blood vessels in cancer patients and cancer survivors could be a new way to prevent or reverse cachexia. The reasons for the muscle loss in cancer are complicated and involve poor nutrition due to loss of appetite and inflammation, which are initially caused by the tumor but persist even when the tumor is removed. What other research is being done There are currently no treatments approved by the Food and Drug Administration for cachexia, but new therapies are on the horizon. One such therapy is an antibody drug that targets the molecule GDF-15, a protein that is thought to suppress appetite. Other studies are using a combination of targeted nutrition and exercise programs to help patients with cancer cachexia regain muscle mass and muscle strength. All these studies suggest that we will need a combination of approaches to enhance exercise, nutrition, appetite, muscle regeneration and – as we propose – blood vessel health. What's next We are now evaluating drugs and exercise programs that are known to improve blood vessel health. Repurposing these treatments that are traditionally designed for cardiovascular patients could be a rapid way to help cancer patients regain muscle strength. We hope that our work highlights how important it is for cancer patients to receive comprehensive medical care, which includes improving cardiovascular health and overall quality of life. Jalees Rehman is Department Chair and Professor of Biochemistry and Molecular Genetics, University of Illinois Chicago. The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts. External Link © The Conversation
